Novartis' Narasimhan Bullish On Cosentyx Keeping Market Lead
This article was originally published in Scrip
Novartis AG hopes new Phase III data showing most patients were able to maintain clear or nearly clear skin for up to three years by using Cosentyx (secukinumab) will reinforce and expand use of its new plaque psoriasis treatment.
You may also be interested in...
Arena's Phase IIb CAPTIVATE trial assessing investigational olorinab in IBS missed its primary endpoint.
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Germany’s Merck has licensed exclusive rights to develop and sell Debiopharm’s potential first-in-class inhibitor of apoptosis proteins (IAP) antagonist, targeting head and neck cancers.